Rats were subcutaneously (SC) injected in the flank, contralateral to the tumor-implanted side, with resiquimod (R848) (Invitrogen, TLRL-R848), a Toll-like receptor 7/8 agonist, at a dose of 100 μg/kg, corresponding to 30 μg/dose, three times per week on Mondays, Wednesdays and Fridays. Here, TLR7 is linked to neoplasm.